|1.||Bonnefoy, J Y: 4 articles (12/2001 - 04/2000)|
|2.||Plotnicky-Gilquin, H: 4 articles (12/2001 - 04/2000)|
|3.||Nguyen, T N: 3 articles (12/2001 - 04/2000)|
|4.||Power, U F: 3 articles (12/2001 - 04/2000)|
|5.||Beck, A: 3 articles (06/2000 - 04/2000)|
|6.||Haeuw, J F: 2 articles (06/2000 - 04/2000)|
|7.||Corvaïa, N: 2 articles (06/2000 - 06/2000)|
|8.||Champion, T: 2 articles (06/2000 - 06/2000)|
|9.||Michaud, V: 1 article (12/2001)|
|10.||Huss, T: 1 article (12/2001)|
04/14/1997 - "The immune response induced by BBG2Na demonstrated a potent protective efficacy against upper and lower respiratory tract RSV-A infection. "
12/01/2001 - "By comparison, primary RSV infection or BBG2Na priming resulted in considerably lower eotaxin and MCP-3 gene expression increases postchallenge, while expression of lymphocyte or monocyte chemoattractant chemokine genes (MIP-1beta, MCP-1, and MIP-2) were of higher magnitude and kinetics at early, but not late, time points. "
12/01/2001 - "Importantly, mice vaccinated with a broad dose range (20 to 0.02 microg) of a clinical formulation of BBG2Na in aluminium phosphate demonstrated histopathology similar to that observed in secondary RSV infection. "
12/01/2001 - "These data were compared and contrasted with data generated following primary and/or secondary RSV infection or RSV challenge following vaccination with a promising subunit vaccine, BBG2Na. "
06/01/2000 - "We have generated a recombinant RSV vaccine, BBG2Na, which is highly protective in rodents against RSV infection. "
|2.||Respiratory Tract Diseases (Respiratory Tract Disease)
|1.||GTP-Binding Proteins (G-Protein)